This company listing is no longer active
Resumen acción VECT
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Competidores de VectivBio Holding AG
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.87 |
| 52 Week High | US$16.98 |
| 52 Week Low | US$4.25 |
| Beta | 0.11 |
| 1 Month Change | 1.93% |
| 3 Month Change | 98.24% |
| 1 Year Change | 193.39% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -30.38% |
Noticias y actualizaciones recientes
Rentabilidad de los accionistas
| VECT | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.1% | 0.1% | 0.9% |
| 1Y | 193.4% | 1.0% | 24.2% |
Rentabilidad frente al sector: VECT exceeded the US Biotechs industry which returned 6% over the past year.
Rentabilidad vs. Mercado: VECT exceeded the US Market which returned 14% over the past year.
Volatilidad de los precios
| VECT volatility | |
|---|---|
| VECT Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: VECT's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: VECT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2019 | n/a | Luca Santarelli | vectivbio.com |
Resumen de fundamentos de VectivBio Holding AG
| Estadísticas fundamentales de VECT | |
|---|---|
| Capitalización bursátil | US$1.06b |
| Beneficios(TTM) | -US$93.73m |
| Ingresos (TTM) | US$27.34m |
38.8x
Ratio precio-ventas (PS)-11.3x
Ratio precio-beneficio (PE)¿Está VECT sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de VECT | |
|---|---|
| Ingresos | US$27.34m |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$27.34m |
| Otros gastos | US$121.08m |
| Beneficios | -US$93.73m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.49 |
| Margen bruto | 100.00% |
| Margen de beneficio neto | -342.84% |
| Ratio deuda/patrimonio | 4.8% |
¿Cómo se ha desempeñado VECT a largo plazo?
Ver rendimiento histórico y comparativa